TICKERNERD
Menu
NGNENGNEHealthcare · Biotechnology

NGNE Stock Forecast: Neurogene, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$36
+1.43% on the day

The 9 Wall Street analysts covering Neurogene, Inc. hold a median 12-month price target of $65 — +79.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$723.2M
Ticker Nerd rank
60 / 100
Median analyst target
$65
Analysts covering
9
Total return, dividends reinvested
1W
+1.3%
1M
−7.5%
YTD
+75.4%
1Y
+78.9%
From 52W high
−15.6%
From 52W low
+120.8%
$16
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NGNE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurogene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
81
Momentum
80
Accruals
78
Value
52
Size
50
Quality
48
Revisions
47
Growth
27
Volatility
25

Issuance (81): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (25): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NGNE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NGNE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Oct 25Jan 26Apr 26Jul 26NGNEHigh $166Median $65Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $46Median $65High $166

The green dot is the last close — the median target sits +79.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
12 Aug 2026Canaccord GenuityMaintainsBuy$180 → $166
12 Aug 2026GuggenheimMaintainsBuy$69 → $81
12 Aug 2026HC Wainwright & Co.MaintainsBuy$70 → $65
9 June 2026HC Wainwright & Co.ReiteratesBuy$70
9 June 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026Canaccord GenuityInitiatesBuy—
26 Jan 2026LifeSci CapitalInitiatesOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
9 Oct 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025Craig-HallumInitiatesBuy—
12 June 2025BMO CapitalMaintainsOutperform—
20 May 2025BMO CapitalMaintainsOutperform—
16 May 2025BairdDowngradeNeutral—
13 May 2025HC Wainwright & Co.MaintainsBuy—
14 Apr 2025BMO CapitalMaintainsOutperform—
25 Mar 2025BairdMaintainsOutperform—
25 Mar 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NGNE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NGNE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Neurogene, Inc. (NGNE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.5×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
2.4×

Cheaper than 42% of US stocks

EV / EBITDA
−4.3×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.3%

Higher than 22% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NGNE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NGNENeurogene, Inc.$723.2M
60
RGNXREGENXBIO, Inc.$703.1M
56
ALLOAllogene Therapeutics, Inc.$679.1M
79
BBOTBridgebio Oncology Therapeutics, Inc.$717.5M
12
CTMXCytomX Therapeutics, Inc.$726.4M
50
ZVRAZevra Therapeutics, Inc.$664.6M
97
DRUGBright Minds Biosciences, Inc.$743.9M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurogene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NGNE news & analysis

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Business Wire · 11 Aug 2026positive

Neurogene (Nasdaq: NGNE) reported its second quarter 2026 financial results and highlighted recent corporate updates, including positive long-term Phase 1/2 data for its NGN-401 program that showed durable, multidomain developmental gains for patients with rare neurological diseases.

Why it matters — NGNE watchers will care because the reported Phase 1/2 data for NGN-401 suggest durable clinical progress in the company's lead program targeting rare neurological conditions.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 4 Aug 2026neutral

Neurogene announced that its Compensation Committee approved inducent grants of non-qualified stock options to purchase an aggregate of 12,555 shares of common stock for four new employees, with a grant date of August 3, 2026, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — NGNE watchers would care because inducement stock-option grants are a standard mechanism the company uses to attract and retain new hires, providing insight into its equity-compensation activity without signaling any change in its clinical or financial outlook.

FAQ

Frequently asked questions about NGNE stock

What is the NGNE stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Neurogene, Inc. have a median 12-month price target of $65, with estimates ranging from $46 to $166. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NGNE stock a buy right now?

Of the 9 analysts covering Neurogene, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurogene, Inc. 60 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NGNE?

As at 15 Aug 2026, Neurogene, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (81 of 100).

Will NGNE stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +79.9% from the last close, and Ticker Nerd's factor model ranks Neurogene, Inc. 60 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NGNE stock forecast for 2030?

No analyst covering Neurogene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGNE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $166 over the next 12 months.

How has NGNE stock performed over the past year?

Neurogene, Inc. returned +78.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurogene, Inc. do?

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases.

What is the latest news on NGNE?

The most recent item we track (Business Wire, 11 Aug 2026): "Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates". Neurogene (Nasdaq: NGNE) reported its second quarter 2026 financial results and highlighted recent corporate updates, including positive long-term Phase 1/2 data for its NGN-401 program that showed durable, multidomain developmental gains for patients with rare neurological diseases.

Company

About Neurogene, Inc.

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its primary purpose is to create purpose-built gene therapies using a biology-first approach, optimizing gene selection, construct design, expression control, and delivery to target neural systems effectively while prioritizing safety. The lead program, NGN-401, is an investigational AAV9 gene therapy delivering the full-length human MECP2 gene under EXACT transgene regulation technology for Rett syndrome, currently in the ongoing Embolden registrational trial evaluating a single dose in females aged three and older. This program has received multiple FDA designations including Breakthrough Therapy, RMAT, Orphan Drug, Fast Track, and Rare Pediatric Disease, along with similar recognitions from EMA and UK MHRA. Neurogene also advances NGN-101 for CLN5 Batten disease, with Phase 1/2 trial enrollment completed and follow-up ongoing. Founded in 2018 and headquartered in New York, NY, Neurogene addresses high unmet needs in rare neurological disorders through innovative gene therapy platforms.

CEO Dr. Rachel L. McMinn Ph.D. · 131 employees · United States · https://www.neurogene.com